ProCE Banner Activity

LEGEND-2 Updated Analysis: Phase I Study of LCAR-B38M CAR T-Cell Therapy in Patients With R/R Multiple Myeloma

Slideset Download
Conference Coverage
Investigational BCMA-targeted CAR T-cell therapy provides tolerable safety profile and high ORR in this early-phase study

Released: December 11, 2018

Expiration: December 10, 2019

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Celgene

Dova Pharmaceuticals

Gilead Text

Incyte

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals, Inc.

Novartis Pharmaceuticals Corporation

Seagen

Takeda Oncology